William Hope - Selected Publications#

Google Scholar h-index 64 i10-index 180; citations 22,602

1. Joseph N Jarvis, David S Lawrence, David B Meya, Enock Kagimu, John Kasibante, Edward Mpoza, Morris Rutakingirwa, Kenneth Ssebambulidde, Lillian Tugume, Joshua Rhein, David R Boulware, Henry C Mwandumba, Melanie Moyo, Henry Mzinganjira, Cecilia Kanyama, Mina C Hosseinipour, Chimwemwe Chawinga, Graeme Meintjes, Charlotte Schutz, Kyla Comins, Achita Singh, Conrad Muzoora, Samuel Jjunju, Edwin Nuwagira, Mosepele Mosepele, Tshepo Leeme, Keatlaretse Siamisang, Chiratidzo E Ndhlovu, Admire Hlupeni, Constantine Mutata, Erik van Widenfelt, Tao Chen, Duolao Wang, William Hope, Timothée Boyer-Chammard, Angela Loyse, Síle F Molloy, Nabila Youssouf, Olivier Lortholary, David G Lalloo, Shabbar Jaffar and Thomas S Harrison Single-dose liposomal amphotericin B treatment for cryptococcal meningitis, New England Journal of Medicine, in press

[first paper to show safety and efficacy of an abbreviated induction regimen for cryptococcal meningitis to facilitate treatment in resource poor settings]

2. Rawson TM, Wilson RC, O'Hare D, Herrero P, Kambugu A, Lamorde M, Ellington M, Georgiou P, Cass A, Hope WW, Holmes AH. Optimizing antimicrobial use: challenges, advances and opportunities. Nat Rev Microbiol. 2021 Jun 22. doi: 10.1038/s41579-021-00578-9.

[review of precision approaches for antimicrobial therapy as a critical adjunct to the development of new compounds for the fight against AMR]

3. Stott KE, Loyse A, Jarvis JN, Alufandika M, Harrison TS, Mwandumba HC, Day JN, Lalloo DG, Bicanic T, Perfect JR, Hope W. Cryptococcal meningoencephalitis: time for action. Lancet Infect Dis. 2021 Apr 16:S1473-3099(20)30771-4. doi: 10.1016/S1473-3099(20)30771-4.

[state-of-the-art review of cryptococcal meningitis as a significant cause of global morbidity and mortality]

4. Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, du Pré S, Livermore J, Bromley MJ, Wiederhold NP, Hope WW, Kennedy AJ, Law D, Birch M. 2016. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A 113:12809–14.

[first description of the first new antifungal class for three decades]

5. Hope W, Stone NRH, Johnson A, McEntee L, Farrington N, Santoro-Castelazo A, Liu X, Lucaci A, Hughes M, Oliver JD, Giamberardino C, Mfinanga S, Harrison TS, Perfect JR, Bicanic T. Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. MBio. 2019 Dec 3;10(6). pii: e02575-19. doi: 10.1128/mBio.02575-19.

[first paper to understand the pharmacodynamics of emergence of resistance to fluconazole in Cryptococcus]

6. Stone NR, Rhodes J, Fisher MC, Mfinanga S, Kivuyo S, Rugemalila J, Segal ES, Needleman L, Molloy SF, Kwon-Chung J, Harrison TS, Hope W, Berman J, Bicanic T. Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. J Clin Invest. 2019 Mar 1;129(3):999-1014. doi: 10.1172/JCI124516. Epub 2019 Jan 28. PubMed PMID: 30688656; PubMed Central PMCID: PMC6391087.

[first paper to understand the molecular mechanisms of resistance for fluconazole in Cryptococcus]

7. Hope WW, McEntee L, Livermore J, Whalley S, Johnson A, Farrington N, Kolamunnage-Dona R, Schwartz J, Kennedy A, Law D, Birch M, Rex JH. 2017. Pharmacodynamics of the orotomides against Aspergillus fumigatus: New opportunities for treatment of multidrug-resistant fungal disease. MBio 8:e01157-17.

[study enabled regimen identification for the very first patients with invasive fungal diseases receiving a new first-in-class antifungal drug]

8. Darlow CA, Docobo-Perez F, Farrington N, Johnson A, McEntee L, Unsworth J, Jimenez-Valverde A, Gastine S, Kolamunnage-Dona R, de Costa RMA, Ellis S, Franceschi F, Standing JF, Sharland M, Neely M, Piddock L, Das S, Hope W. Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0029321. doi: 10.1128/AAC.00293-21.

[Study providing evidence for combination regimen for treatment of neonatal sepsis and now being studied in a global trial by GARDP]

9. Negri CE, Johnson A, McEntee L, Box H, Whalley S, Schwartz JA, Ramos-Martín V, Livermore J, Kolamunnage-Dona R, Colombo AL, Hope WW. 2018. Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. J Infect Dis 217:1118–1127.

[evidence of the activity of the orotomides against Aspergillus flavus, which is an important cause of global sinusitis]

10. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee D-G, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann A-H, Zeiher B, Ullmann AJ. 2016. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet (London, England) 387:760–9.)

[definitive clinical study of isavuconazole for invasive mould diseases leading to labeling and recognition of isavuconazole as a first-line treatment]

Imprint Privacy policy « This page (revision-4) was last changed on Monday, 20. June 2022, 09:46 by System
  • operated by